Venrock Adviser, LLC
NEW YORK, NY · CIK 1615982 · 13F filing filed 2023-05-15
SEC-registered investment adviser since 2014 · limited liability company
- Assets managed$4.5bn
- Staff11 · 11 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds7 (1 hedge) · $4.5bn gross assets
- Form ADV · 2026-04-28SEC adviser record
- Legal entityVENROCK ADVISER, LLC (US)
- Kindhedge funds, private equity
- Others nearbyNew York, NY, Palo Alto, CA
As an employer
- Offices in1 country
- Private fundshedge 1, private equity 6
Where they work
Offices
From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.
| City | People |
|---|---|
| New York, NY (main office)United States | about 11 |
| Palo Alto, CAUnited States |
Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.
$512.2m
reported value
-13.7% vs Q4 2022
25positions
73.7%in top 10
4 new
5 added
2 reduced
7 sold out
vs Q4 2022
Holdings, Q1 2023
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| VIRIDIAN THERAPEUTICS INC VRDN | $68.7m13.41% | Unchanged |
| COGENT BIOSCIENCES INC COGT | $52.7m10.29% | Added +846.9k |
| ENLIVEN THERAPEUTICS INC ELVN | $48.5m9.47% | New |
| TERNS PHARMACEUTICALS INC COM | $42.9m8.37% | Reduced -88.4k |
| PLIANT THERAPEUTICS INC PLRX | $38.0m7.43% | Added +350.0k |
| AMBRX BIOPHARMA INC SPONSORED ADS | $29.4m5.74% | New |
| GH RESEARCH PLC GHRS | $28.1m5.49% | Unchanged |
| DICE THERAPEUTICS INC COM | $23.5m4.58% | Unchanged |
| KALVISTA PHARMACEUTICALS INC KALV | $22.9m4.48% | Unchanged |
| MERUS N V MRUS | $22.6m4.41% | Unchanged |
| CELCUITY INC CELC | $21.6m4.21% | Unchanged |
| AEROVATE THERAPEUTICS INC COM | $16.8m3.28% | Added +86.1k |
| CABALETTA BIO INC CABA | $16.3m3.19% | Added +78.0k |
| VECTIVBIO HLDG AG ORD SHS | $15.9m3.10% | Unchanged |
| ANNEXON INC ANNX | $12.4m2.42% | Unchanged |
| SAVARA INC SVRA | $12.4m2.42% | Unchanged |
| MILESTONE PHARMACEUTICALS IN MIST | $8.7m1.70% | Unchanged |
| ACLARIS THERAPEUTICS INC ACRS | $8.4m1.64% | Reduced -3.5m |
| THESEUS PHARMACEUTICALS INC COM | $6.8m1.34% | New |
| TREVI THERAPEUTICS INC TRVI | $5.6m1.10% | Unchanged |
| FULCRUM THERAPEUTICS INC FULC | $3.7m0.73% | Added +859.8k |
| LYRA THERAPEUTICS INC LYRA | $1.9m0.36% | Unchanged |
| AVALO THERAPEUTICS INC COM NEW | $1.8m0.34% | New |
| RALLYBIO CORP COM | $1.5m0.30% | Unchanged |
| AFFIMED N V COM | $1.1m0.21% | Unchanged |
Sold out since Q4 2022
| Security | Value then |
|---|---|
| AXSOME THERAPEUTICS INC AXSM | $51.7m670.7k shares |
| NOVAVAX INC NVAX | $19.3m1.9m shares |
| PROVENTION BIO INC PRVB | $11.8m1.1m shares |
| LIANBIO LIANY | $7.9m4.8m shares |
| MARINUS PHARMACEUTICALS INC MRNS | $7.0m1.8m shares |
| INOZYME PHARMA INC | $2.8m2.7m shares |
| ATYR PHARMA INC ATYR | $2.6m1.2m shares |